About Tempus AI
Tempus AI news and updates
T. Rowe Price Group invests into Tempus Labs, Inc. in $100M
Tempus has raised a $100 million Series G from Baillie Gifford, Franklin Templeton, NEA, Novo Holdings and T. Rowe Price at a valuation of $5 billion.
Jan 1, 2020 | pitchbook.comA2biotherapeutics partnered with Tempus Labs, Inc. on Jan 13th 21'.
A2, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, is collaborating with Tempus to validate its leading xT sequencing assay to specifically identify patients with the LOH genetic alteration.
Jan 1, 2021 | globalbankingandfinance.comTempus Labs, Inc. integrates with Cedars Sinai
In order to make the information in the Molecular Twin database accessible and actionable for both physicians and researchers, Tempus is integrating it with Cedars-Sinai's electronic medical records system.
Jan 1, 2021 | precisiononcologynews.comTempus Labs, Inc. partnered with Wildfrontierstravel on Jan 1st 22'.
To that end, Tempus has teamed up with adventure tour operator Wild Frontiers for a look at some of the most intriguing and romantic itineraries available for newlyweds this year.
Jan 1, 2022 | tempusmagazine.co.ukTempus Labs, Inc. launched EDGE on Mar 21st 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of EDGE, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
Jan 1, 2022 | businesswire.comTempus Labs, Inc. launched Edge on Mar 21st 22'.
Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
Jan 1, 2022 | hitconsultant.netZentalis Pharmaceuticals partnered with Tempus Labs, Inc. on Feb 25th 21'.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the company’s patient-derived organoid biological modeling platform to strengthen Zentalis’ discovery and research capabilities.
Jan 1, 2021 | biospace.comTempus Labs, Inc. integrates with Cedars-Sinai
In order to make the information in the Molecular Twin database accessible and actionable for both physicians and researchers, Tempus is integrating it with Cedars-Sinai's electronic medical records system.
Jan 1, 2021 | genomeweb.comTempus Labs, Inc. launches psychiatric real-world data program
Tempus, an $8B precision medicine company, announced the launch of a new psychiatric real-world data program to leverage real-world data to inform mental health treatment.
Jan 1, 2022 | hitconsultant.netTempus Labs, Inc. launched Tempus N+ on May 20th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to power precision medicine solutions through the use of real-world data for mental health.
Jan 1, 2022 | businesswire.comTempus Labs, Inc. launches xF+
Medical technology firm Tempus is set to expand its comprehensive genomic profiling offering with the launch of xF+, it’s new non-invasive, liquid biopsy panel.
Jan 1, 2022 | medicaldevice-network.comTempus Labs, Inc. partnered with Eli Lilly & Co. on Jun 10th 22'.
June 10, 2022 -- Artificial intelligence (AI) developer Tempus is partnering with Eli Lilly to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC).
Jan 1, 2022 | scienceboard.netThe Life Raft Group partners with Tempus Labs, Inc.
Considering this, The Life Raft Group is collaborating with Tempus Labs and Bayer Pharmaceuticals to provide GIST patients, who fit a certain criteria, to have this testing performed at no cost.
Jan 1, 2022 | liferaftgroup.orgCedars Sinai partners with Tempus Labs, Inc.
Cedars-Sinai Cancer has joined with precision-medicine firm Tempus to design personalized cancer treatments.
Jan 1, 2022 | cedars-sinai.orgTempus Labs, Inc. partnered with Intermountain on Jun 16th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients.
Jan 1, 2022 | tempus.comTempus Labs, Inc. partnered with Intermountain on Jun 16th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients.
Jan 1, 2022 | tempus.comGeneCentric Therapeutics, Inc. partnered with Tempus Labs, Inc. on Sep 13th 22'.
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurIST℠, a novel RNA-expression test, in collaboration with Tempus.
Sep 13, 2022 | businesswire.comTempus Labs, Inc. partnered with Children’s Oncology Group on Sep 20th 22'.
Tempus, an $8B precision medicine company, is providing genomic sequencing for 300 eligible pediatric cancer patients annually through their new collaboration with the Children’s Oncology Group (COG).
Sep 19, 2022 | hitconsultant.netTempus Labs, Inc. partnered with Kartos Therapeutics, Inc. on Oct 6th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232).
Oct 6, 2022 | businesswire.comTempus Labs, Inc. partnered with GlaxoSmithKline on Jan 13th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline or somatic PALB2 mutation.
Jan 12, 2022 | businesswire.comAres Management LLC invested into Tempus Labs, Inc. in $275M on Oct 13th 22'.
Biotech upstart Tempus announced on Thursday it raised $275 million through equity from previous investors and debt financing from Ares Management...
Oct 17, 2022 | crunchbase.comTempus Labs, Inc. hired Kate Sasser as Chief Scientific Officer on Oct 25th 22'.
Tempus, a leader in artificial intelligence and precision medicine, today announced that Kate Sasser, PhD, is joining the company as its Chief Scientific Officer.
Oct 24, 2022 | tempus.comTempus Labs, Inc. acquired Arterys Inc. on Oct 22nd 22'.
Arterys has been recently acquired by Tempus, a technology company advancing precision medicine through the practical application of AI.
Oct 5, 2022 | pressrelease.comFight Colorectal Cancer partners with Tempus Labs, Inc.
Fight Colorectal Cancer partnered with Tempus to think outside of the box and together Fight Colorectal Cancer worked to find a way to increase access to the data to benefit colorectal cancer patients and the cancer research community.
Dec 15, 2022 | fightcolorectalcancer.orgMayo Clinic partnered with Tempus Labs, Inc. on Jan 1st 17'.
Last year, Mayo Clinic invested in a partnership with technology startup Tempus to use Artificial Intelligence and machine learning to analyze cancer patients and develop personalized care for more patients.
Jan 4, 2017 | dynam.ai